More recently, immune checkpoint inhibitors (anti-PD-1/PD-L1) have revolutionized the treatment of many tumors with most remarkable benefits in the patients with melanoma, non-small cell lung carcinoma, renal cell carcinoma, bladder carcinoma, and classical Hodgkin lymphoma [42]. Here, PDCD1 is linked to melanoma.